CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - NYSE:CRL - US1598641074 - Common Stock
171.5 USD
-2 (-1.15%)
171.5 USD
0 (0%)
Overall CRL gets a fundamental rating of 4 out of 10. We evaluated CRL against 58 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CRL was profitable.
CRL had a positive operating cash flow in the past year.
Each year in the past 5 years CRL has been profitable.
In the past 5 years CRL always reported a positive cash flow from operatings.
1.2 Ratios
CRL's Return On Assets of -1.11% is in line compared to the rest of the industry. CRL outperforms 58.62% of its industry peers.
Looking at the Return On Equity, with a value of -2.45%, CRL is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
With a decent Return On Invested Capital value of 5.84%, CRL is doing good in the industry, outperforming 74.14% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CRL is significantly below the industry average of 13.50%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROIC | 5.84% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
In the last couple of years the Profit Margin of CRL has declined.
CRL's Operating Margin of 11.73% is fine compared to the rest of the industry. CRL outperforms 72.41% of its industry peers.
CRL's Operating Margin has been stable in the last couple of years.
CRL's Gross Margin of 34.68% is on the low side compared to the rest of the industry. CRL is outperformed by 62.07% of its industry peers.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
CRL has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRL has more shares outstanding
CRL has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.42 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score of 2.42. This is in the better half of the industry: CRL outperforms 62.07% of its industry peers.
CRL has a debt to FCF ratio of 4.02. This is a neutral value as CRL would need 4.02 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4.02, CRL is doing good in the industry, outperforming 74.14% of the companies in the same industry.
A Debt/Equity ratio of 0.64 indicates that CRL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.64, CRL is not doing good in the industry: 68.97% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Altman-Z | 2.42 |
ROIC/WACC0.58
WACC9.98%
2.3 Liquidity
A Current Ratio of 1.37 indicates that CRL should not have too much problems paying its short term obligations.
CRL's Current ratio of 1.37 is on the low side compared to the rest of the industry. CRL is outperformed by 79.31% of its industry peers.
CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL has a Quick ratio of 1.10. This is in the lower half of the industry: CRL underperforms 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.25%.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
The Revenue has decreased by -0.92% in the past year.
Measured over the past years, CRL shows a quite strong growth in Revenue. The Revenue has been growing by 9.09% on average per year.
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
3.2 Future
The Earnings Per Share is expected to grow by 6.43% on average over the next years.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 2.43% on average per year.
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.71%
EPS Next 5Y6.43%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.16%
Revenue Next 5Y2.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.26, which indicates a correct valuation of CRL.
Compared to the rest of the industry, the Price/Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 93.10% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.34. CRL is valued slightly cheaper when compared to this.
CRL is valuated correctly with a Price/Forward Earnings ratio of 15.77.
Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 93.10% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CRL to the average of the S&P500 Index (34.43), we can say CRL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.26 | ||
| Fwd PE | 15.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 96.55% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 91.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.52 | ||
| EV/EBITDA | 11.7 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.82
EPS Next 2Y2.66%
EPS Next 3Y4.71%
5. Dividend
5.1 Amount
CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
171.5
-2 (-1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.46%
Inst Owner Change-1.27%
Ins Owners0.88%
Ins Owner Change6.42%
Market Cap8.44B
Revenue(TTM)4.02B
Net Income(TTM)-83.48M
Analysts72.17
Price Target192.74 (12.38%)
Short Float %4.3%
Short Ratio2.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.28%
Min EPS beat(2)2.88%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)10.51%
Min EPS beat(4)2.88%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.19%
EPS beat(12)12
Avg EPS beat(12)8.5%
EPS beat(16)16
Avg EPS beat(16)6.77%
Revenue beat(2)2
Avg Revenue beat(2)2.06%
Min Revenue beat(2)0.38%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.12%
Min Revenue beat(4)0.38%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.53%
Revenue beat(12)10
Avg Revenue beat(12)1.83%
Revenue beat(16)12
Avg Revenue beat(16)1.25%
PT rev (1m)5.46%
PT rev (3m)17.19%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)-1.61%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)6.11%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)3.17%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)2.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.26 | ||
| Fwd PE | 15.77 | ||
| P/S | 2.1 | ||
| P/FCF | 15.52 | ||
| P/OCF | 11.26 | ||
| P/B | 2.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.7 |
EPS(TTM)10.55
EY6.15%
EPS(NY)10.88
Fwd EY6.34%
FCF(TTM)11.05
FCFY6.44%
OCF(TTM)15.23
OCFY8.88%
SpS81.77
BVpS69.2
TBVpS-1.79
PEG (NY)N/A
PEG (5Y)1.82
Graham Number128.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROCE | 7.39% | ||
| ROIC | 5.84% | ||
| ROICexc | 6.03% | ||
| ROICexgc | 13.86% | ||
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% | ||
| FCFM | 13.51% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Debt/EBITDA | 2.43 | ||
| Cap/Depr | 48.19% | ||
| Cap/Sales | 5.12% | ||
| Interest Coverage | 4.36 | ||
| Cash Conversion | 83.34% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.42 |
F-Score4
WACC9.98%
ROIC/WACC0.58
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.71%
EPS Next 5Y6.43%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.16%
Revenue Next 5Y2.43%
EBIT growth 1Y-22.72%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year34.27%
EBIT Next 3Y14.36%
EBIT Next 5Y10.95%
FCF growth 1Y47.54%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y7.42%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
Can you provide the valuation status for CHARLES RIVER LABORATORIES?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 16.26 and the Price/Book (PB) ratio is 2.48.
How financially healthy is CHARLES RIVER LABORATORIES?
The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.